These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 16126372)

  • 1. Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Nachshoni T; Ebert T; Abramovitch Y; Assael-Amir M; Kotler M; Maayan R; Weizman A; Strous RD
    Schizophr Res; 2005 Nov; 79(2-3):251-6. PubMed ID: 16126372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of clinical symptomatology, extrapyramidal symptoms and neurocognitive dysfunction following dehydroepiandrosterone (DHEA) administration in olanzapine treated schizophrenia patients: a randomized, double-blind placebo controlled trial.
    Strous RD; Stryjer R; Maayan R; Gal G; Viglin D; Katz E; Eisner D; Weizman A
    Psychoneuroendocrinology; 2007 Feb; 32(2):96-105. PubMed ID: 17208382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia.
    Strous RD; Maayan R; Lapidus R; Stryjer R; Lustig M; Kotler M; Weizman A
    Arch Gen Psychiatry; 2003 Feb; 60(2):133-41. PubMed ID: 12578430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of sustained attention and visual and movement skills, but not clinical symptoms, after dehydroepiandrosterone augmentation in schizophrenia: a randomized, double-blind, placebo-controlled, crossover trial.
    Ritsner MS; Gibel A; Ratner Y; Tsinovoy G; Strous RD
    J Clin Psychopharmacol; 2006 Oct; 26(5):495-9. PubMed ID: 16974191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movement disorder, memory, psychiatric symptoms and serum DHEA levels in schizophrenic and schizoaffective patients.
    Harris DS; Wolkowitz OM; Reus VI
    World J Biol Psychiatry; 2001 Apr; 2(2):99-102. PubMed ID: 12587192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum levels of brain-derived neurotrophic factor and cortisol to sulfate of dehydroepiandrosterone molar ratio associated with clinical response to L-theanine as augmentation of antipsychotic therapy in schizophrenia and schizoaffective disorder patients.
    Miodownik C; Maayan R; Ratner Y; Lerner V; Pintov L; Mar M; Weizman A; Ritsner MS
    Clin Neuropharmacol; 2011; 34(4):155-60. PubMed ID: 21617527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive deficits in schizophrenia are associated with alterations in blood levels of neurosteroids: a multiple regression analysis of findings from a double-blind, randomized, placebo-controlled, crossover trial with DHEA.
    Ritsner MS; Strous RD
    J Psychiatr Res; 2010 Jan; 44(2):75-80. PubMed ID: 19665142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevation of the cortisol/dehydroepiandrosterone ratio in schizophrenia patients.
    Ritsner M; Maayan R; Gibel A; Strous RD; Modai I; Weizman A
    Eur Neuropsychopharmacol; 2004 Aug; 14(4):267-73. PubMed ID: 15163435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The retinoid X receptor agonist bexarotene relieves positive symptoms of schizophrenia: a 6-week, randomized, double-blind, placebo-controlled multicenter trial.
    Lerner V; Miodownik C; Gibel A; Sirota P; Bush I; Elliot H; Benatov R; Ritsner MS
    J Clin Psychiatry; 2013 Dec; 74(12):1224-32. PubMed ID: 24434091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
    Potkin SG; Saha AR; Kujawa MJ; Carson WH; Ali M; Stock E; Stringfellow J; Ingenito G; Marder SR
    Arch Gen Psychiatry; 2003 Jul; 60(7):681-90. PubMed ID: 12860772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortisol/dehydroepiandrosterone ratio and responses to antipsychotic treatment in schizophrenia.
    Ritsner M; Gibel A; Maayan R; Ratner Y; Ram E; Biadsy H; Modai I; Weizman A
    Neuropsychopharmacology; 2005 Oct; 30(10):1913-22. PubMed ID: 15870835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial.
    Ritsner MS; Gibel A; Shleifer T; Boguslavsky I; Zayed A; Maayan R; Weizman A; Lerner V
    J Clin Psychiatry; 2010 Oct; 71(10):1351-62. PubMed ID: 20584515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to antipsychotic therapy among patients with schizophrenia or schizoaffective disorder and either predominant or prominent negative symptoms.
    Stauffer VL; Song G; Kinon BJ; Ascher-Svanum H; Chen L; Feldman PD; Conley RR
    Schizophr Res; 2012 Feb; 134(2-3):195-201. PubMed ID: 22019076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in DHEA metabolism in schizophrenia: two-month case-control study.
    Ritsner M; Gibel A; Ram E; Maayan R; Weizman A
    Eur Neuropsychopharmacol; 2006 Feb; 16(2):137-46. PubMed ID: 16139994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of the CYP2D6 polymorphism on psychopathological and extrapyramidal symptoms in the patients on long-term antipsychotic treatment.
    Plesnicar BK; Zalar B; Breskvar K; Dolzan V
    J Psychopharmacol; 2006 Nov; 20(6):829-33. PubMed ID: 16478753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
    Lohr JB; Liu L; Caligiuri MP; Kash TP; May TA; Murphy JD; Ancoli-Israel S
    Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of the safety and tolerability of high-dose quetiapine in patients with persistent symptoms of schizophrenia or schizoaffective disorder.
    Honer WG; MacEwan GW; Gendron A; Stip E; Labelle A; Williams R; Eriksson H;
    J Clin Psychiatry; 2012 Jan; 73(1):13-20. PubMed ID: 21733490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study.
    Nasrallah HA; Silva R; Phillips D; Cucchiaro J; Hsu J; Xu J; Loebel A
    J Psychiatr Res; 2013 May; 47(5):670-7. PubMed ID: 23421963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.